Pseudoephedrine sale restriction — GPhC CRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Decline the combination because pseudoephedrine and ephedrine products cannot be sold in one transaction
The restriction is transaction-specific: it is unlawful to sell a pseudoephedrine-containing product and an ephedrine-containing product together, even when each product is below its separate content ceiling. The individual limits of 720 mg pseudoephedrine and 180 mg ephedrine remain additional controls. These routine Pharmacy-medicine sales do not require a controlled-drug-register entry.
Reference: MHRA: Pseudoephedrine and ephedrine sales restrictions: https://www.gov.uk/drug-safety-update/pseudoephedrine-and-ephedrine-regular-review-of-minimising-risk-of-misuse-in-the-uk